A2M management have completely missed the boat on this one. BUB BOD proactive and got the result, A2M reactive and slow to react. disappointed to say the least considering they already have their tentacles in the US market, hoping for good results across Q4 and FY reporting
Ann: Deferral of FDA consideration of enforcement discretion, page-2
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$7.80 |
Change
-0.040(0.51%) |
Mkt cap ! $5.647B | |||
| Open | High | Low | Value | Volume |
| $7.79 | $7.89 | $7.78 | $17.05M | 2.179M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7486 | $7.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.80 | 63 | 1 |
View Market Depth
| Last trade - 16.20pm 26/06/2025 (20 minute delay) ? |
| A2M (ASX) Chart |